Such evidence could therefore imply that PP2A-B56δ holoenzyme may be involved in the regulation of SOX9 proteasomal degradation, via AKT inhibition and GSK-3β activation, thereby contributing to the development of cHCC-CCA tumors. Here, GSK3B is linked to cholangiocarcinoma.